Abstract:Key PointsCNS remyelination is the regenerative process by which myelin sheaths are restored to demyelinated axons. Unlike the poor regeneration that occurs following neuronal injury, remyelination can occur as a spontaneous and efficient process in experimental models and many clinical conditions.Although remyelination can occur in multiple sclerosis (MS; a widely occurring demyelinating disease), it often fails, leaving axons demyelinated and vulnerable to degeneration. Recent studies have revealed the importance of the myelin sheath for maintaining axonal integrity and hence the importance of promoting remyelination in diseases such as MS as an effective means of neuroprotection.Remyelination is mediated by a population of adult neural stem cells that are widely distributed throughout the CNS and that are commonly referred to as oligodendrocyte precursor cells (OPCs). These cells respond to demyelination by activation, proliferation, migration and finally differentiation into remyelinating oligodendrocytes; it is the last of these processes that is most likely to fail in MS and leave areas of demyelination containing oligodendrocyte-lineage cells that are unable to fully differentiate.Remyelination is governed by a complex interaction of environmental signals and cell-intrinsic mechanisms that are triggered by the inflammatory response to injury. This response therefore has a key role in initiating remyelination. The network of signals that is involved in remyelination shows high levels of redundancy.In theory, remyelination can be enhanced either by promoting endogenous remyelination or by transplanting myelinating cells. The first approach, which may have a pharmacological basis, is especially attractive for diseases such as MS in which remyelination occurs and will involve either the antagonism of negative regulatory pathways and/or the enhancement of positive regulatory pathways.Cell therapy (transplantation) approaches to remyelination are expected to be of particular benefit for genetic demyelinating diseases in which there is an inherent defect in the oligodendrocyte lineage. Recent studies have provided proof-of-principle that human cells can be used to remyelinate the entire CNS in laboratory animal models.

Cell-based remyelinating therapy in inflammatory demyelinating injury of the CNS

Remyelination in the CNS: from biology to therapy

Central nervous system regeneration: the roles of glial cells in the potential molecular mechanism underlying remyelination

Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials

Cell‐based experimental strategies for myelin repair in multiple sclerosis

Repair of Myelin Disease: Strategies and Progress in Animal Models

Remyelinating Pharmacotherapies in Multiple Sclerosis

Remyelination in multiple sclerosis: cellular mechanisms and novel therapeutic approaches

Mechanisms of Demyelination and Remyelination Strategies for Multiple Sclerosis

Emerging myelin repair agents in preclinical and early clinical development for the treatment of multiple sclerosis

[Mechanisms Underlying Remyelination with Special Focus on Demyelination Models of Multiple Sclerosis].

Strategies for myelin regeneration: lessons learned from development

[Neuroscience] Remyelination in the Central Nervous System

Clinical Applications of Myelin Plasticity for Remyelinating Therapies in Multiple Sclerosis

Accelerated Remyelination During Inflammatory Demyelination Prevents Axonal Loss and Improves Functional Recovery

Demyelinating processes in aging and stroke in the central nervous system and the prospect of treatment strategy

Promoting Remyelination in Central Nervous System Diseases: Potentials and Prospects of Natural Products and Herbal Medicine

Remyelinating Drugs at a Crossroad: How to Improve Clinical Efficacy and Drug Screenings

Promoting peripheral myelin repair

Overview of emerging therapies for demyelinating diseases

Regenerative Capacity of Macrophages for Remyelination